1Melanoma Institute Australia, North Sydney, NSW
2Sydney Medical School, The University of Sydney, Camperdown, NSW
3Immunogenomics Laboratory, Australian National University, Canberra, ACT
4Oncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, Qld
5Centre for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead, NSW
6Bioplatforms Australia, Macquarie University, North Ryde, NSW
7Ludwig Institute for Cancer Research, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Vic
8The Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Vic
9Departments of Melanoma and Surgical Oncology
10Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; these authors contributed equally
Address for correspondence: Prof Richard A. Scolyer, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia. E-mail: [email protected]
Received 18 March, 2015
Revised 22 June, 2015
Accepted 28 June, 2015
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.rcpa-pathologyjournal.com).